Charles River’s Decision Shows Misunderstanding of Pharma’s Future

This week's announcement that some of Charles River Laboratories’ investors blocked the deal to acquire WuXi Apptec is remarkable in several aspects. Most importantly, Charles River is passing up a one-time opportunity to establish near-complete global dominance in its industry. The deal significantly undervalued WuXi because it ignored the strategic value of WuXi itself, which is the dominant player in the world's most important emerging market. More details... Stock Symbols: (NYSE: WX) (NYSE: CRL)